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ABSTRACT 
BACKGROUND 
 The incidence of HPV associated HNSCC is increasing over the past 30 
years. It is a growing public health concern. It has been reported that tissues of 
HPV associated HNSCCs over express p16INK4a . Therefore p16INK4a is 
used as a surrogate marker to detect HPV associated HNSCC. 
Immunohistochemical detection of p16INK4a is an easy and simple technique 
than molecular detection of HPVs. Hence we investigated the presence of 
p16INK4a in HNSCCs. 
OBJECTIVES 
 The objectives of our study are (1)To study the association of 
p16INK4a expression with HNSCC, thus with the HPV. (2)To compare the 
p16INK4a expression in different subsites of the HNSCC. (3)To correlate the 
level of p16INK4a expression with different grades of HNSCC. 
MATERIALS AND METHODS 
 A total sample of 60 cases were analysed during the period of June 
2014 to August 2015. We performed IHC detection in sections of formalin 
fixed paraffin embedded tissue of HNSCC cases and correlated the various 
patterns of p16INK4a positivity with respect to histopathological diagnosis.  
RESULTS 
 In the present study, 75% of the HNSCC cases were above 50 years of 
age. HNSCC was more common in males with male to female ratio of 6:1 .  
93.33% of HNSCC cases were positive for p16INK4a, of which the most 
common pattern was diffuse nuclear and cytoplasmic staining (53.33%). 
CONCLUSION 
 In the present study, increased number of HNSCC cases were seen over 
expressing p16INK4a (93.33%). Oropharynx was the most common site for 
p16INK4a positivity in HNSCC cases (94.44%). Among the oral cavity SCC 
cases, tongue was the most common site involved (64%). Of the HNSCC 
cases, most cases (53.33%) had diffuse pattern of p16INK4a over expression. 
However, DNA detection based studies are needed to validate the utility of 
IHC detection of p16INK4a as a surrogate marker for HPV associated 
HNSCC. 
Key words 
HNSCC,  p16INK4a,  HPV,  Head and neck cancer,  Squamous cell 
carcinoma          
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INTRODUCTION 
Oropharyngeal and Upper Respiratory Tract Squamous Cell Carcinoma 
or Head and Neck Squamous Cell Carcinoma ( HNSCC ) is a global health 
problem with high prevalence and mortality rate across the world. Every year 
approximately 6,00,000 cases have been reported in HNSCC, worldwide
1
. 
This is the sixth most common cancer group, causing 2,00,000 deaths every 
year. The incidence is much higher in India, Southeast Asia and Europe
2
. It is 
the top ranked among all cancers in males and got third in females
3
. Almost 
90% of carcinoma reported in HNSCC. It usually develops from oropharynx, 
oral cavity, larynx and hypopharynx. Oral lesions like leukoplakia, 
erythroplakia, and lichen planus have an increased risk for transformation to 
malignancy in oral cavity
4
. The distribution of oral carcinoma in India varies 
from state to state. The prevalence of oral carcinoma across the country has 
shown marked increase in Uttar Pradesh, Madhya Pradesh, Gujarat, Bihar and 
Maharashtra
5
.  
The risk factors of HNSCC are multifactorial; many epidemiological 
study data commend the association between the HNSCC with tobacco use, 
active and passive. Smokeless tobacco usage and alcohol consumption are also  
important causes
6,7
. In the last two decades the study about Human Papilloma 
Virus (HPV) in HNSCC showed a unique cause of malignancy
8
. Uterine 
cervix carcinogenesis risk factor HPV is now well recognized as the risk factor 
of HNSCC, which shown a marked increased prevalence rate
9
. The 
transmission of HPV infection through body fluids, oral sex is an important 
18 
 
transmission type. The concurrence of HPV in HNSCC was established by 
Syrjanen et al. in 1983 and many researchers supported the fact on the basis of 
evidence.   
Statistical data collected about the prevalence of HPV in HNSCC in 
2013 shown 36% of contribution and it is a double the value of previous 
decade data
10
. It is estimated, after 5 years HNSCC will overcome the 
prevalence of Cervical Carcinoma. It is more prevalent in younger people, less 
than 60 years in whom there is a decreasing rate of smoking and increase in 
the transmission of HPV among youngsters. The increased incidence rate 
shown in the age of 40 to 50 years without any environmental risk factors, is 
associated with the continual infection with HPV
11,12
. Many researchers were 
working on determining the possible viral causing factor, mainly the 
oncogenic HPV. The effect of high alcohol consumption which may also leads 
to the HPV infection due to the alteration of mucosal membrane
13
.  
More than 99% of cervical carcinoma is due to the HPV 16, 18 and 33 
subtypes, globally. The epithelial cell specific HPV is a group of host specific 
DNA virus with more than 120 of subtypes, almost 4 subtypes has been 
studied in cervical carcinoma. Subtypes 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 
81 and 89 are considered as low oncogenic effect viruses which can be 
isolated from low grade epithelial cell
14,15,16
 . HPV 16 is the commonest 
subtype in HNSCC. There is an increased risk of HNSCC in the patient 
diagnosed with cervical carcinoma. The HPV infection is also traced in benign 
oral lesions as condyloma acuminata, common warts, oral papilloma, focal 
epithelial hyperplasia and in potentially malignant or premalignant 
19 
 
erythroplakia, erythro-leukoplakia and leukoplakia, and proliferative 
verrucous leukoplakia
17
. The exact origin of HPV infection in HNSCC is not 
clear; it usually starts from the reticulated epithelium of oropharynx, which 
lines the crypts of the palatine tonsils and base of tongue. The irregular and 
deep shaped crypts in the tonsils allow for the exposure of HPV pathogen 
within the lymphoepithelial tissue
18,19
 .  
The mechanism of HNSCC in HPV negative patients is frequent DNA 
mutation. HPV positive HNSCC are due to the genetic alterations. The 
oncogenic proteins E6 and E7 released by the high risk virus subtypes 
interrupt the p53 and pRb tumor suppressing pathways respectively, which 
leads to increased cell proliferation and genomic instability leading to 
carcinogenesis. p16
INK4a
 is one of the several cyclin-dependent kinase 
inhibitors responsible for regulation of normal cell cycle. As pRb is 
inactivated by E7 protein, cells are released from growth-suppressive stimuli 
mediated by the p16
INK4a
. Thus reduced or lost pRb function results in 
enhanced p16
INK4a
 levels, as a result of a negative feedback control
9
. p16
INK4a
 
is commonly used as a biomarker for transcriptionally active HPV-associated 
cancers
20,21,22
. 
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AIMS AND OBJECTIVES 
1. To study the association of p16INK4a expression with head and neck 
squamous cell carcinoma, thus with the Human papilloma virus. 
2. To compare the p16INK4a expression in different sites of the head and 
neck  squamous cell carcinoma. 
3. To correlate the level of p16INK4a expression with different grades of 
head and neck  squamous cell carcinoma. 
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REVIEW OF LITERATURE 
Oropharyngeal and Upper Respiratory Tract Squamous Cell Carcinoma 
or Head and Neck Squamous Cell Carcinoma ( HNSCC ) is the world fifth 
most common cancer in worldwide. Squamous Cell Carcinoma is the most 
common malignancy which has high incidence of more than 600000 cases 
every year and high morbidity worldwide
1,2
 . Squamous cell carcinoma occurs 
in 5 anatomical sites oral cavity, oropharynx, nasopharynx, hypopharynx and 
larynx
4
 . Human papilloma virus (HPV) positive HNSCC is highly associated 
with oral sex behavior. The main risk factors of squamous cell carcinomas are 
tobacco users, alcohol users and oral sex
23
 .  
There is an association between HPV positive HNSCC with sexual 
behavior, but not in HPV negative HNSCC
 24
 . Tobacco use is the main cause 
of HNSCC with as high as 80% of cases attributed to it. Alcohol usage acts 
synergistically with tobacco in the increased incidence of HNSCC
25
. There is a 
decrease in the incidence of HNSCC due to reduction of tobacco use but there 
is a remarkable increase in the incidence due to HPV infection
26
 . HPV 
infected HNSCC has genetic alteration, influenced by HPV oncoproteins E6 
and E7 which inactivate the tumor suppressing gene
27
 .  
Historical aspects 
Papilloma viruses were first identified from rabbits in 1933. They were 
transmissible and found to cause benign papillomas. 
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HPV was first identified in 1956 and associated with a variety of 
benign growths in humans
28
 . 
HPV has subsequently been shown to be the cause of many types of 
human cancer.         
HPV was first implicated in cancer biology forty years ago by Harald 
zur Hausen. He was awarded Nobel Prize in Physiology or Medicine in 2008 
for the discovery of HPV causing cervical cancer. After that, HPV is also 
associated with other anogenital cancers like vulvar, penile and anal, mainly 
due to sexual transmission. Recently, high risk HPV is detected in HNSCCs, 
particularly in the oropharynx, previously caused mainly by tobacco and 
alcohol consumption
29
 .  
Gissmann et al first described the HPV presence in the head and neck 
region in 1982. They noted HPV DNA in patients with laryngeal papillomas. 
Then, Syrjanen et al detected HPV antigens in oral squamous cell lesions in 
1983.  
In 1989, Brandsma and Abramson detected HPV 16 DNA in the 
oropharynx, specifically the palatine tonsils, in two of the seven tonsillar 
squamous cell carcinomas
30
 . 
Since then more data have come, implicating HPVs in the oncogenesis 
of HNSCC, predominantly OPSCC. 
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Normal anatomy
31
  
 
Fig 1. Head and neck region 
Oral cavity and posterior tongue 
Most of the oral cavity is lined by non keratinized, stratified squamous 
epithelium except for certain regions where the epithelium becomes 
keratinized. 
Non Keratinized mucosa constitutes from the basement membrane to 
the surface, stratum basale stratum spinosum (prickly) and a superficial layer. 
In Keratinized epithelium, stratum granulosum and stratum corneum 
(keratinized layer) are existing above the stratum spinosum. 
Molecular study show stratum basale are the only cell type which 
expresses proliferation allied antigens and the RNA component of telomerase. 
24 
 
These basal cells replace the dedicated cells that undergo terminal 
differentiation in the major superficial layers of the epithelium. Thus basal 
cells ensure the epithelium‘s turnover and have the role of stem cells. 
Regional variations in the composition of the epithelium like its 
quantity of keratinization reflect differences in the amount of mechanical 
stress during mastication which depends on the resiliency of the exposed 
areas.   
Buccal mucosa has extended mucosal ridges anchoring it to severly 
collagenized lamina propria. Areas secured from stress such as the floor of 
mouth, possess thinner and shallower rete ridges and less collagenized lamina 
propria. 
In the posterior third of tongue lingual mucosa has lymphoid tissue, 
part of the mucosa – associated lymphoid tissue. 
The level of  keratinization, thickness, presence of pigments and the 
extent of  vascularization of mucosa and lamina propria concern the colour of 
the mucosa. These features are effective when correlating the clinical 
appearance of mucosal lesions with their microscopic appearance. 
Oral cavity has small salivary glands within its submucosa. Intra 
epithelial neoplasia together with in situ carcinoma, can involve both the acini 
and excretory ducts of minor salivary glands which can mimic invasive 
carcinoma. 
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Lip 
Lymphatics of the central part of the lower lip drain to the sub mental  
nodes. Lymphatics from the rest of the lower lip pass to the submandibular 
nodes.  
Cheek 
Lymphatics of the cheek drain chiefly into the submandibular and 
preauricular nodes and party also to the buccal and mandibular nodes. 
Floor of the mouth 
Lymphatics from the anterior part of the floor of the mouth pass to the 
submental nodes. Those from the hard palate and soft palate pass to the 
retropharyngeal and upper deep cervical nodes. The gums and the rest of the 
floor drain into the submandibular nodes. 
Gums 
Lymphatics of the upper gums pass to the submandibular nodes. The 
anterior part of the lower gums drains into the submental nodes, whereas the 
posterior part drains into the submandibular nodes.  
Hard palate 
The blood supply of the hard palate is from the greater palatine branch 
of maxillary artery. 
The venous drainage is into the pterygoid plexus of veins. 
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The lymphatics of the hard palate drain mostly to the upper deep 
cervical nodes and partly to the retropharyngeal  nodes.  
Soft palate 
Blood supply of the soft palate is from the Greater palatine branch of 
maxillary artery, Ascending palatine branch of facial artery and Palatine 
branch of ascending pharyngeal artery. 
Venous drainage pass to the pterygoid and tonsillar plexuses of veins. 
Lymphatic of the soft palate drain into the upper deep cervical and 
retropharyngeal lymph nodes. 
Tongue 
Arterial supply is by the lingual artery a branch of the external carotid 
artery. Root of the tongue is also supplied by the tonsillar branch of facial 
artery and ascending pharyngeal branch of external carotid artery. 
Venous drainage of the tongue: Two venae comitantes accompany the 
lingual artery and one vena comitantes accompanies the hypoglossal nerve. 
Deep lingual vein is the largest and principal vein of the tongue. These 
veins unite at the posterior border of the hyoglossus to form the lingual vein 
which ends in the internal jugular vein. 
Lymphatic drainage of the tongue: Tip of the tongue drains bilaterally 
to the  submental nodes. 
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Right and left halves of the remaining part of the anterior two-thirds of 
the tongue drain unilaterally to the submandibular nodes. A few central 
lymphatics drain bilaterally to the same nodes. 
Posterior one third of the tongue drains bilaterally to the jugulo-
omohyoid nodes, these are known as lymph nodes of the tongue. 
Posterior most part of the tongue drains bilaterally into the upper deep 
cervical lymph nodes. 
Pharynx 
Pharynx is divided into three compartments:  Oropharynx,  
nasopharynx and hypopharynx. 
Both oropharynx and hypopharynx are lined by stratified non 
keratinized squamous epithelium with submucosal compartments having 
seromucinous glands and aggregates of lymphoid tissue. 
In the nasopharynx 60% is lined by stratified non keratinized squamous 
epithelium and leftover 40% by pseudostratified, ciliated, respiratory type 
epithelium. 
The pseudostratified, ciliated, respiratory type epithelium predominates 
in the posterior nares and in the roof of posterior wall. 
Other areas reveal an alteration of the two types of epithelia. 
At the alteration between the two types, the mucosa has an intermitted 
or transitional appearance that may mimic intraepithelial neoplasia. 
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Low magnification of the mucosa in these areas may appear a 
moderately disorganized architecture, also called as incomplete metaplasia, 
which may mimic true dysplasia. 
Higher exaggeration classically reveals preserved maturation and lack 
of frank nuclear atypia, often coupled with the presence of ciliated layer in the 
vicinity of these areas. 
Similar characters are seen at the transition between squamous and 
respiratory epithelia in the larynx in regular conditions and in squamous 
metaplasia in the bronchial ciliated epithelium in response to irritants. 
Palatine Tonsil 
Arterial supply of the tonsil is mainly from Tonsillar branch of facial 
artery. Additional sources of arterial supply are  
Ascending palatine branch  of facial artery, Dorsal lingual branches of 
the lingual artery, Ascending  pharyngeal branch of the external carotid artery 
and Greater palatine branch of the maxillary artery. 
Venous drainage pass to the palatine, pharyngeal or facial veins. 
Lymphatic  drainage pass to  jugulodigastric node.  
Pharynx 
Arterial supply of the pharynx are Ascending pharyngeal branch of the 
external carotid artery, Ascending palatine  and  tonsillar branches of the facial 
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artery, Dorsal lingual  branches of the lingual artery and Greater palatine, 
Pharyngeal and pterygoid branches of the maxillary artery. 
Venis form a plexus on the posterolateral aspect of the pharynx.  The 
plexus receives blood from the pharynx, soft palate and the prevertebral 
region. It drains into the internal jugular and facial veins.  
Lymphatics of the pharynx drains into the retropharyngeal and deep 
cervical lymph nodes.  
Larynx 
Normal laryngeal mucosal lining also varies to some extent in 
thickness, like in the oral cavity. Thick keratinizing surface epithelial lining is 
controlled to laryngeal glottis. The thicker keratinized epithelium of the glottis 
prevents the mucosa from repetitive mechanical trauma of phonation. 
The remaining epithelial lining of the larynx changes according to the 
location and shows alteration of ciliated, respiratory type and squamous 
epithelia. 
The supraglottic compartment extends from the tip of the epiglottis to 
the inferior border of false vocal cord. It shows respiratory epithelium. 
True vocal cords are lined by squamous epithelia. 
The subglottic larynx is the portion of larynx among the lower border of true 
vocal cord and first tracheal ring. It is lined by the respiratory mucosa. 
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The respiratory epithelium is ciliated pseudostratified epithelium. 
Similar to squamous mucosa, the basal cells are the regenerative part of the 
respiratory epithelium. The modified cells in the luminal surface are composed 
of ciliated, brush and goblet cells, allowing mucociliary clearance. A minor 
component of the epithelium is constituted by small granular cells, have 
neurosecretory granules and belong to the diffuse neuroendocrine system. 
These cells are detected only by electron microscopy or special immuno histo 
chemical stains. 
Like in the pharynx, areas between the squamous and respiratory- type 
epithelia have transitional appearance. 
In nearly half of smokers, patches of squamous metaplasia are seen in 
the supraglottic larynx. 
Arterial supply up to the vocal folds is by the superior laryngeal artery, 
a branch of the superior thyroid artery. 
Below the vocal folds is supplied by the inferior laryngeal artery, a 
branch of the inferior thyroid artery. 
Venous drainage up to the vocal folds is by the superior laryngeal vein 
which drains into the superior thyroid vein. 
Below the vocal folds is by the inferior laryngeal vein which drains into 
the inferior thyroid vein. 
Lymphatics from above the vocal folds drain along the superior thyroid 
vessels to the anterosuperior group of deep cervical nodes. 
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Below the vocal folds drain to the postero inferior group of deep 
cervical nodes. A few of them drain through the prelaryngeal nodes. 
Epidemiology  
The association of HPV infection in HNSCC has attracted the 
researchers in the past 25 years due to the high incidence rate. The incidence 
of HNSCC in many countries has been increased significantly. In 1970 the 
incidence of HPV infected tonsillar and carcinoma in the base of the tongue 
has been reported by Nasman et al. in the Stockholm region. The incidence 
rate has been increased from 23% in 1970 to 93% in 2007
32
 . The concomitant 
increase of HPV infected HNSCC than tobacco associated HNSCC is due to 
the reduction on tobacco usage among youngsters group. The increase in the 
HPV associated HNSCC is due to the sexual behavior changes among the 
youngsters. Oral sex is most common among youngsters group which relate to 
the incidence of HPV infection
33
 . HPV infected Oropharynx carcinoma 
incidence in higher than the other anatomical site, it is reported that 
oropharynx is five times more likely to be infected by HPV than oral cavity, 
larynx
34
 . The prevalence of HPV infection in different population group has 
been studied - 9.3% in Sweden, 2.3% in Australia, 0.6% in Japan, 6.95% in 
United States
35
 . All HPV infections won‘t progress to carcinoma. Slow 
clearance of virus has been shown to be risk on the development of anogenital 
carcinoma. HPV infected Oropharyngeal Squamous Cell Carcinoma (OPSCC) 
has been increasing significantly. In the 2008 report, among 85000 of OPSCC, 
22000 cases are reported as HPV positive. There is a increase of 225% HPV 
infected HNSCC cases from 1988 to 2004 in United states with 50% decreases 
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in HPV negative cases
36
 . The same trend has been reported in Europe and 
Australia. The overall incidence rate of HPV positive OPSCC is 25.6% 
worldwide, which may vary according to geographical region. The proportion 
of HPV-positive OPSCC was 56% in North America; 52% in Japan; 45% in 
Australia; 39% in Western and Northern Europe; 38% in Eastern Europe; 17% 
in Southern Europe; and 13% in the rest of the world
35
.  The incidence of HPV 
positive HNSCC is higher among persons having multiple sexual partners, 
middle aged, not using tobacco or alcohol. HPV positive cases usually clear in 
own but some of the viral DNA integrates with host genome; this is the main 
cause of inducing HPV carcinogenesis. The survival rate is high in HPV 
positive HNSCC cases than HPV negative cases
37
 .  
Squamous cell carcinoma of the Oral cavity 
Carcinomas of oral cavity are commonly situated in the base of the 
tongue and tonsils. These tumours are mostly undifferentiated and solid and 
resemble large cell malignant lymphoma. The epithelium surrounding the 
tumour shows dysplastic changes. The squamous cell carcinomas that show 
eosinophilic infiltration are associated with good prognosis. Perineurial and 
vascular invasions are common if immunohistochemical markers are done
38
.  
Squamous cell carcinoma of the Oropharynx 
The squamous cell carcinoma of oropharynx are less differentiated 
when compared to squamous cell carcinoma of oral cavity. 
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Squamous cell carcinoma of the Larynx 
Laryngeal carcinomas usually occur as a protruding mass of pink or 
gray colour and they are usually ulcerated. Lesions of the vocal cord are 
keratotic. Nearly 90% of the laryngeal carcinomas are squamous cell type. On 
the degree of differentiation, cellular pleomorphism and mitotic activity they 
are classified into well, moderately and poorly differentiated
39
. The tumour 
that are situated in the subglottic region are smaller in size are well 
differentiated. The tumour that has minimal stromal invasion, within 0.5mm 
from the basement membrane are called as minimally invasive, microinvasive 
or superficially invasive. The mobility of cord is not affected. The evolution of 
invasive carcinoma from in situ carcinoma is associated with replacement of 
CD-34 positive stromal cells by smooth muscle positive myofibroblasts. 
Variants of Squamous cell carcinoma 
I.  Verrucous Carcinoma 
In oral cavity verrucous carcinoma are marcroscopically, seen as a large 
fungating, soft papillary growth. They are often infected and invade the soft 
structure of the cheek and penetrate the maxilla or mandible and invade the 
perineurial tissues. They invade the nodes very rarely. 
Verrucous carcinoma are well differentiated and so it is difficult to 
diagnose it microscopically. A superficial biopsy will show benign 
papillomatosis. Adequate biopsy will show swollen and voluminous rete pegs 
extending into the deeper tissues and have complex pattern
40
. The good 
differentiation through out the tumour differentiate if from squamous cell 
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tumour. The cells of verrucous carcinoma are larger than the cells of 
squamous cell carcinoma. In 20% of the cases foci of squamous cell 
carcinoma occurs with in verrucous carcinoma. This type usually have a high 
rate of recurrence. 
In the larynx also they are macroscopically a polypoidal growth and 
microscopically they are well differentiated. They invade locally but rarely 
have distant metatasis
41
. Verrucous carcinoma closely resembles verrucous 
hyperplasia. They are differentiated by the presence or absence of invasion 
and it is difficult to be diagnosed with a small blopsy. Hybrid carcinoma also 
occur in laryngeal cancer. Surgery is the means of treatment. Radiation 
therapy was given when there is an anaplastic transformation. 
II.  Adenoid (Pseudoglandular) squamous cell carcinoma 
Mostly they are situated in the lip and the underlying factor is actinic 
radiation. They may rarely present in gingiva or tongue where actinic radiation 
have no role
42
. They have a pseudoglandular or alveolar appearance. 
III.  Adenosquamous carcinoma 
These are rare tumours. They have squamous differentiation amidst true 
glandular differentiation
43,44
. Some tumours may be from minor salivary 
glands but they are different from mucoepidermoid carcinomas. 
IV. Basaloid  squamous cell carcinoma 
In oral cavity, this is the most aggressive from. They commonly occur 
in the oral cavity, oropharynx, oesophagus and larynx. They may occur rarely 
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in the lung also. The ‗cloacogenic carcinoma‘ of the anal canal may also 
resemble basaloid carcinoma. They mildly resemble adenocarcinoma. 
Histogentically they mimic adenosquamous carcinoma but microscopically 
they are different. Basaloid carcinoma have areas of clear squamous 
differentiation mixed with solid tumour and have peripheral palisading and a 
thick basement membrane
45
.  
They have cystic spaces filled with mucoid and hyaline material and 
they resemble adenoid cystic carcinoma. The classical feature of this tumour is 
the prominence of basal lamina at both ultrastructurally and immunohisto 
chemically. The tumour immunoreact for high molecular weight keratin 
(detected with the 34βE12 antibody) consistently. 
In the larynx also it has an aggressive course. It usually occurs in heavy 
smokers. It is characterized by hyperchromatic nuclei, scanty cytoplasm, 
necrosis and peripheral palisading. There is an attempt to differentiate 
torwards glandular structures. This tumour may also occur in tongue, pharynx 
and oesophagus. It should not be confused with adenoid cystic carcinoma. 
V. Papillary Squamous Cell Carcinoma 
It is usually found in the oropharynx of elderly patients and it is usually 
HPV positive. 
In the larynx it occurs as an exophytic growth. It is usually associated 
with human papilloma virus and have a good prognosis when compared to the 
one in sinonasal region
46
 . It is differentiated from verrucous carcinoma by its 
cytological atypia. 
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VI.  Spindle cell (sarcomatoid) Carcinoma 
They are usually ulcerated and appear as an infiltrative mass or as a 
polypoid growth in the lip, tongue or other parts of oral cavity. The sarcoma 
like lesions are usually mixed with squamous cell carcinoma. They may be 
found as a recurrence of previously diagnosed squamous cell carcinoma. 
These along with electron microscopic, immunohistochemical and molecular 
data shows that the sarcomatoid component indicates a metaplastic change of 
an original epithelial neoplasm. Immunostains help to differentiate between 
sarcomatiod and sarcoma. The immunostains are epithelial membrane antigen, 
(EMA) membranous epithelial cadherin and nuclear p63. The sarcoma like 
component mimic malignant fibrous histocytoma. It may show evidence of 
specific mesenchymal differentiation along the muscle lines. Hyaline globules 
is seen in the cytoplasm of larger cells
. 
The prognosis depends on the depth of 
invasion. 
Sarcomatoid tumour of the larynx usually occur as a polypoidal 
growth
47
 and mimic a laryngeal polyp. Microscopically, they have both 
squamous cell component and sarcoma like component. The sarcomatoid 
component may mimic as granulation tissue or appear like malignant fibrous 
histiocytoma, malignant giant cell tumour or osteosarcoma. 
Risk Factors  
The risk factors of HPV positive HNSCC are similar to the HPV 
positive cervical squamous cell carcinoma. The patients with HPV positive 
HNSCC are younger age group with less tobacco and alcohol intake
48
. 
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Molecular profile of HPV positive and HPV negative HNSCC differentiate 
distinctly and shows the similarity of the HPV positive cervical squamous cell 
carcinoma. The similarities of the HPV positive cervical carcinoma cases are 
younger age, age at first intercourse, oral sex, number of sexual partners
49.
  
 
Table 1. 
Although many HNSCC have multifaceted risk factors, tobacco, 
alcohol and sexual behavior are the major risk factors of the HNSCC. Various 
international health agencies have conclusively reported that tobacco use is the 
main cause of 8 major carcinomas in maximum 13 sites which include 
HNSCC. Mortality rate of tobacco users is high when compared with never 
smokers. The risk of tobacco causing carcinoma increases with increase in 
consumption of tobacco
50
.  
Study reveals that most of the HNSCC patients are alcohol users. There 
is no study to support alcohol and tobacco use as the independent risk factor of 
the HNSCC. The level of alcohol consumption is taken as factor when 
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considering alcohol as one of the risk factors of HNSCC. There is no such 
study to report with daily alcohol use, but the reasonable to assume, if increase 
in alcohol use may lead to risk of HNSCC
 51
.  
The combination of tobacco and alcohol use has been reported as 
increased risk of HNSCC. When high use of alcohol and tobacco excerpt the 
synergetic effect on increasing the risk of HNSCC
 52
. 
Viruses like herpes group, adenoviruses and HPV influence in the 
molecular events governing the cell cycles. Cellular oncogenes, also known as 
proto-oncogenes, acquire their transforming properties or become activated by 
gene amplification, point mutations, and gene rearrangements
53
. HPV and 
herpes group of viruses are now considered as the synergistic viruses which 
are involved in many HNSCC. More than 100 genotypes have been isolated 
from benign and malignant neoplasms. The most isolated genotypes are HPV 
16 and HPV 18, they are also found in normal oral mucosa. HPV infection 
HNSCC has genetic alteration of influenced by HPV oncoproteins E6 and E7 
which inactivate the tumor suppressing gene
54
.   
HPV oncoproteins E6 and E7 plays major role in immunocompetence, 
which alters the intercellular immune mechanism. The HPV oncoproteins are 
capable of binding with many human gene products, particularly the gene 
deregulating control of cell proliferation and differentiation
55
.  
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HPVs and molecular mechanisms of HPV-induced carcinogenesis 
 
Fig 2. HPV-16 Genome 
Human papilloma virus is a Double stranded DNA virus, which is 
episomal. There are 200 types of known HPV, only few are cancer causing 
virus. Most of the HPV are infecting the human epithelial cells and connected 
with different anatomic site preference non-mucosal and cutaneous 
epithelium
56
. International Agency of Research on Cancer classified HPV 
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 as carcinogenic and type 68 
as probably carcinogenic to humans
57
. These HPV types are more responsible 
for the cervical cancer and other sites. Further the HPV is sub-divided into low 
risk and high risk by the ability of the virus to transform into the host cell. 
HPV 16, 18, 31, 45 subtypes are categorized as high risk types which is 
responsible for the cervical cancer and HPV 6, 11 types are low risk 
subtypes
58
.  
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Fig 3.  Schematic presentation of the events involved in cancer 
development after HPV infection 
 
Table 2. High risk HPV types 
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The double stranded HPV genome consists of approximately 8000 
pairs, divided into 3 regions: a noncoding ―long control region‖ (LCR) 
regulating gene expression and replication, and 2 protein-coding regions, the 
early (E1-E7) region coding proteins required for gene expression, replication 
and survival, and the late (major L1 and minor L2) region coding capsid 
proteins involved in packaging of viral genome and virus release
59
. The early 
genes encode 3 viral oncoproteins E5, E6 and E7. E6 and E7 plays a major 
role both benign proliferation and malignant transformation. E6 and E7 of 
HPV 16 (and of the other HR types) are able to induce degradation of the 
tumor suppressor protein p53and pRb via the ubiquitin pathway
60
. The cellular 
protein E6AP binds with E6, this complex E6/E6AP accountable for the 
ubiquitination and proteasomal degradation of p53 protein. The p53 plays a 
role of safeguarding the cell, but there would be a malfunction of p53 in many 
human malignancies.  
This is reported as p53 mutations, happen in HPV infection carcinoma 
p53 is degraded by E6 oncoproteins
61
. The step toward malignant formation is 
chromosomal instability of the cells expressing HPV 16 E6 oncoproteins. 
HPV E7 binds with transcription factor E2F and inactivates the pRb through 
proteasomal degradation, which controls the G1 S phase transition of cell 
cycle progress, apoptosis, mitosis and differentiation. Cyclin A and Cyclin E 
will be activated after E2F release, which leads the entry of cells into G1 S 
phase. The inactivation of pRb leads to the increased induction of p16
INK4a
. 
Tumor suppressor p16
INK4a 
is used as biomarker for HPV positive infection 
lesions and cancer. Most of the HPV positive HNSCC show p16
INK4a 
over 
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expression. In the HPV negative HNSCC, tobacco and alcohol usage lead to 
mutational loss of p16
INK4a
 and p53 genes. P16 oncogenic effect depends on 
the inhibition of CDK4/CDK6 in Rb inactivated cancer cells. CDK4/CDK6 
substrate present in cells with inactivated Rb, when phosphorylated may cause 
cell death
62,63,64 
. 
 
Fig 4 . Proposed oral HPV natural history 
Diagnostic (Detection) Methods for HPV-Positive Oropharyngeal and 
Upper Respiratory Tract Squamous Cell Carcinoma 
HPV Positive HNSCC do not require the status of HPV evaluation. 
Many institutions doing this as the standard care for the HPV Positive 
HNSCC. HPV induced HNSCC have different tumor entity and 
histopathological features and improved prognosis. Nevertheless, 
heterogeneity in both biological and clinical behaviour among HPV positive 
cases has been observed in many studies. This is due to the different viral gene 
expression and viral load and highlights the need of HPV evaluation in tumor 
using an algorithm that detects the biologically active HPV, and identifies the 
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cases with improved outcome
65,66,67,68
. There is no consensus on the optimal 
way to identify HPV positive HNSCC. Molecular detection is the Gold 
Standard for detection of HPV DNA in tissues and exfoliated cells samples. 
Southern blot test is one of the oldest methods to detect HPV DNA with low 
false positive rates and high sensitivity, and also has the ability to identify the 
HPV subtypes.   
Southern blot is not suited for routine clinical use due to time intensive 
and require large quantities of cellular DNA. Detection of p16 expression 
using Immunohistochemistry (IHC) has less specificity than southern blot 
test
69,70,71
. Polymerase chain reaction (PCR) is used to detect the p16 
expression as well as the genetic material related to HPV within the small 
tumor samples. PCR leads to false positive results, high sensitivity to viral 
genome that may be present in oral tissues but that are not related to cancer. In 
situ hybridization (ISH) is used to detect the HPV subtypes; it has lower 
specificity than Southern blot test. The presence of HPV specific antibodies in 
serum has also been associated with the risk of developing HNSCC
 72,73
. 
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Table 3. 
p16
 INK4a
 ImmunoHistoChemistry ( IHC ) 
The standard test for detecting HPV involvement in tumor is detection 
of Cyclin-dependent kinase inhibitor 2A (p16
INK4a
 protein) over expression, 
which is a suitable surrogate biomarker and used as the first level of clinical 
assessment. The over expression of tumor suppression gene p16
INK4a 
is during 
the immortalization of the host cells, high risk HPV E7 results in 
downregulation of Rb thus freeing E2F. Free E2F results in upregulation of 
p16
INK4a
. The quick, inexpensive method of detection of p16
INK4a
 has become 
the standard for clinical assessment but it should be noted that all p16
INK4a
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positive tumors are not HPV positive. 10% to 20% of p16
INK4a
 positive 
HNSCC have shown no evidence of HPV infection. Few studies reported that 
no over expression of p16
INK4a
 was observed in patients who were positive for 
HPV DNA and mRNA. Furthermore, a study demonstrated an over expression 
of p16
INK4a
 in young patients with oral tongue Squamous Cell Carcinoma 
without evidence of HPV infections. One more study also showed that OPSCC 
patients who were p16
 INK4a
 -positive and seronegative for HPV antibodies had 
poor prognosis
73-76
. From these reports, we infer that p16
 INK4a 
over expression 
alone is not sufficient to correctly identify HPV infection in HNSCC. But, p16
 
INK4a 
IHC alone is used as a choice by many clinicians, because it is widely 
studied and cost effective with clear staining interpretation guidelines. In the 
future, DNA and RNA based methods for HPV identification will become 
necessary along with    p16
 INK4a 
IHC.  
HPV DNA Detection 
HPV DNA Polymerase Chain Reaction ( PCR ) 
The high sensitive and cost effective method of detection of HPV DNA 
strains, targeting to amplify fragments of the conserved HPV L1 gene are 
commonly used to detect the broad spectrum of HPV such as MY09/MY11 
and GP5/GP6 primer pairs. The MY09/MY11 primer pair is synthesized with 
several degenerate nucleotides in each primer and is thus a mixture of 25 
primers capable of amplifying a wide spectrum of HPV types
76,77,78
. 
Tumorigenic E6 and/or E7 sequence, which is retained by infected cells 
through viral genome integration, may prove to be more sensitive in the 
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detection of HPV. Standard PCR techniques have low specificity and do not 
allow for a distinction between tumor-derived or healthy stroma-derived HPV. 
Furthermore, PCR techniques are not able to distinguish between episomal 
and integrated HPV DNA, thus decreasing the ability to detect clinically 
relevant infection
79,80
. 
HPV DNA In- Situ Hybridisation ( ISH ) 
A method to detect HPV DNA in tumor samples. It has a high 
specificity compared to PCR method. It detects and identifies HPV in 
topographical relationship with their pathological lesions. The appearance of 
precipitate within the nuclei of epithelial cells indicates HPV presence, which 
can be seen microscopically. Also, integrated and episomal HPV DNA are 
distinguished by the presence of punctuate or diffuse signals, respectively. 
HPV DNA presence defected by ISH, significantly correlated with p16
INK4a
 
IHC. Despite the high specificity of this method (100%), sensitivity is low 
(86%). Therefore, it gives 13-41% false negative rate in HNSCC
 81,82,83
. 
HPV RNA Detection 
HPV RNA Polymerase Chain Reaction ( PCR ) 
PCR method of detecting mRNA is a good approach of detecting HPV 
infection than DNA detection. PCR mRNA detection method provide more 
clinically relevant evidence of HPV infection than DNA detection. The 
mRNA expression from episomal HPV DNA indicates the viral oncogenic 
transcript is crucial in tumor initiation and progression. The over expression 
E6 and E7 has been detected in HPV positive, tumor samples. The E6/E7 
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mRNA expression has been shown to highly in HPV positive tonsillar 
squamous cell carcinoma and lower in oropharyngeal. The instability of the 
RNA and suboptimal preservation of the biopsy samples using formalin-fixed 
paraffin-embedded (FFPE) analyses, the methods discussed thus far for HPV 
transcript detection rely on the analysis of fresh-frozen tissue in research 
laboratories, therefore hampering the translation to routine clinical diagnostic 
test. High risk HPV E6/E7 mRNA ISH has been developed as a potential 
detection tool in FFPE tissues
84,85,86
. 
HPV RNA In- Situ Hybridisation ( ISH ) 
Recently, high risk HPV E6/E7 mRNA ISH is developed as a potential 
detection tool in FFPE tissues. In a study of Oropharyngeal squamous cell 
carcinoma patients, RNA ISH was positive in 99.3%  of p16
INK4a
 – positive 
tumors and had a better sensitivity in HPV detection than DNA ISH. Schache 
et al reported sensitivity and specificity of 97% and 93% respectively, in the 
detection of high risk HPV using RNA ISH in FFPE Oropharyngeal squamous 
cell carcinoma samples
87,88,89
. Hence, detection of HPV transcripts is highly 
concordant with active and clinically relevant HPV infection which can be 
incorporated into the current clinical diagnostic methods.  
HPV DNA and RNA ISH which have high specificity is used in 
combination with P16 IHC or HPV DNA PCR which have high sensitivity are 
effective in diagnosis of HPV associated HNSCC. Screening tumors with 
p16
INK4a
 IHC is to be performed first, and if the result is positive, to be 
followed by HPV – specific test, such as ISH or PCR. This provides evidence 
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that HPV is in the tumor and that the HPV is transcriptionally active based on 
P16 over expression and E6/E7 mRNA expression levels
90
.  
HPV Serology 
HPV serology is used to detect the previous and current HPV infection 
status using IgG in serum samples. It is an important biomarker to know the 
status of the HPV infection. These serological biomarkers are not site specific 
biomarker; it can arise due to HPV infection at sites other than oral cavity. The 
HNSCC patients with HPV positive E6 and E7 seropositive showed a 
favorable cause of survival compared to seronegative patients
91,92
.  
HPV Detection in Oral fluid  
Recently, the use of biological markers in oral fluids for the detection 
of HPV associated HNSCC is gaining attention, due to the non invasive and 
cost effective nature, as well as the proximity to oral tumors, which allows 
early cancer detection and monitoring of disease progression. Oral fluids may 
allow detection of HPV and cellular alterations in infected cells, which may 
aid in early detection and typing of HNSCC tumors
93,94
 .  
A study of oral exfoliated cells and tumor tissues from HNSCC patients 
showed significant correlation between HR – HPV detected in oral rinse and 
high risk HPV types present in tumor tissues. Assessment of HPV genotypes 
in oral rinse may be predictive of HPV associated HNSCC and HPV infection 
is a risk factor for HNSCC independent of alcohol and tobacco use
95
. 
Comparing the use of swabs or scrapes to collect mucosal cells from a limited 
number of oral sites, use of oral rinse is likely to have sampled the tumor site 
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and the localised field of HPV infection. Another study utilized real  time 
quantitative PCR (RT-qPCR) to detect HPV 16 E6 and  E7 DNA in oral rinses 
for screening HNSCC. RT-qPCR enables more accurate quantification of HPV 
DNA copy number present in samples with high sensitivity than non 
quantitative amplification methods. 45.7% of primary tumor tissues and  
32.6%   oral rinses from HNSCC patients had detectable HPV 16 DNA
96
. 
HPV DNA detection in tumor tissues and oral rinse from patients with 
tumors demonstrated significant correlation (P<0.001). A recent prospective 
study demonstrated that HPV detection in oral rinse was comparable with 
HPV presence in tumor tissues. Earlier study showed the presence of HPV 
DNA in tumor tissues and in oral rinse samples and was associated with 
presence of  HPV  specific antibodies in sera. There is a feasibility of 
correlating high risk HPV DNA positivity in oral rinses and HPV- related 
antibodies in the blood for detection and surveillance of disease progression
97
.  
The presence of high risk HPV DNA in oral samples may be a strong 
biomarker for development of OPSCC in high risk groups with premalignant 
lesions and immuno compromised individuals. A recent study analysed and 
correlated presence of HPV DNA in oral samples (oral rinses and /or tonsillar 
swabs) in patients with incidence of HPV positive tonsillar and base of tongue 
cancer. Presence of HPV DNA in oral samples that is concordant with HPV 
positivity in tumor samples was detected in 76% and 50% of patients with 
tonsillar and base of tongue cancer, respectively
98,99
 .  
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Studies to data have demonstrated promising data for the utilization of 
oral fluid as a valid specimen for detection of high risk HPV. At present, there 
is only one laboratory based salivary diagnostic test available to detect HPV, 
by detecting different strains of HPV such as HPV 8,11,16 and 18 via PCR 
using oral rinse samples. However, the sensitivity and specificity of oral fluid 
based detection methods lack experimental evidence. It is also important to 
experimentally validate if the HPV infection is current/active or in the past. 
Oral fluid based tests to determine HPV infection require further 
improvements because of the different origins of cells being tested in oral 
fluid. 
Clinical features of HPV-induced Oropharyngeal and Upper Respiratory 
Tract Squamous Cell Carcinomas 
HPV positive HNSCC is more likely to be young aged, non-tobacco 
users, mild to moderate alcohol users. HPV positive HNSCC patients are 
having multiple sex partners or having oral sexual behavior. Patients with 
HPV positive HNSCC have high survival rate than HPV negative patients. 
HPV induced squamous cell carcinoma develops from oropharynx and base of 
the tongue being more commonly involved in HNSCC
 100,101,102
. Tonsillar 
crypts covered with reticulated epithelium which has contact with immune 
system may prone to HPV infection and subsequent malignant 
transformation
103
. There are no specific histologic features to discriminate the 
HPV induced from non-HPV induced squamous cell carcinoma. Identification 
of HPV positive and HPV negative HNSCC is important to identifying the 
specific targets in each subjects and understanding the pathogenesis to provide 
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the targeted therapies. The morphological characters of HPV driven 
carcinogenesis, while the prototypic HNSCC is moderately distinguished 
HPV-induced SCCs are predominantly non-keratinizing SCC often described 
as poorly differentiated carcinomas or basaloid carcinomas based on the 
lobular growth of cells with hyperchromatic nuclei, scanty cytoplasm and 
marked mitotic activity
104,105,106,107
 . HPV positive HNSCC have specific 
clinical presentation of tumor and neck stage. Compared to non-HPV related 
carcinomas, HPV related carcinomas are diagnosed in an earlier of T-category 
with a trend for a more advanced N-category
108
.  
Prognosis of HPV-induced Oropharyngeal and Upper Respiratory Tract 
Squamous Cell Carcinomas 
The evidence of HPV induced HNSCC came from various single site 
retrospective case series studies published in the last decades, shown that HPV 
positive HNSCC cases particularly the oropharyngeal carcinoma patients 
treated with radiotherapy, chemotherapy, surgery and combined modality 
therapy shown better outcome than the HPV negative HNSCC cases
 109-112
. 
These studies shown there is reduction of risk of disease failure when 
compared HPV positive squamous cell carcinoma with HPV negative patients. 
The reason behind the HPV positive HNSCC better prognosis than HPV 
negative cases remains elusive. The overall survival rate of HPV positive 
cases depend on the younger age at diagnosis,alower tobacco and alcohol use, 
distinct biology of cancer, reduced risk of secondary tumor or aggressive 
treatment strategy. The favorable outcome of HPV-induced SCC may be 
attributableato enhanced sensitivity to treatment due to a wild-type TP53, 
52 
 
allowing an apoptotic response of cancer cells to radiation and chemo 
radiation
113
. Tobacco use may alter the clinical behaviour of the HPV positive 
HNSCC adversely affecting the prognosis. The high risk HPV E6 and E7 
oncoproteins target tumor suppressor signaling pathways. A major 
transforming characters of HPV16 E6 is its ability to induce perversion of the 
tumor suppressor protein p53 via the ubiquitin pathway in transcriptionally 
active HPV infections, HPV16 E7 inactivates pRb. This event is connected 
with up-regulation of CDKN2A, which codes for1 p16
INK4a
. The absence of 
TP53 gene mutations is significantly associated with better overall survival 
and p16
INK4a
 positivity, irrespective of HPV status, is also associated with 
better outcomes
114
 . 
Management of HPV - Positive Oropharyngeal and Upper Respiratory 
Tract Squamous cell carcinoma. 
Treatment of HPV positive HNSCC is a serious problem, as although 
there is no clear evidence from randomized, controlled trial to support the 
reduction of treatment intensity in HPV positive Squamous cell carcinoma. 
Some researchers argued, that intensive concomitant chemoradiation therapy 
amounts to overtreatment. HPV positive patients are younger, an 
multimodality strategy, which may resultain high rates of acute and long term 
severe toxicity would not be suitable for prolonged survival. In this situation, 
efforts are taken to reduce the toxicity and increase the quality of life in long 
term, while maintaining the efficacy
115-117
 .  
53 
 
In strengthening the treatment for HPV positive squamous cell 
carcinoma patients, including altered radiation fractionation and the 
combination of chemotherapy and altered radiation fractionation, patients still 
have the problem of significant challenge of recurrent or second tumors 
arising within short period. Locally recurrent tumors may arise from residual 
neoplastic cells that survive initial treatment, perhaps because of biological 
parameters that confer radio-resistance or insufficiencies in initial treatment 
parameters such as radiation dose, volume, fractionation and treatment 
duration. A treatment de-escalation would be achievedaby reducing the total 
dose of radiotherapy as well as the dose of chemotherapy
118
 .   
Many researches are mainly based on the reducing the intensity of the 
radiotherapy or on substituting cis-platinum with cetuximab in concurrent 
chemotherapy regimens. Furthermore emerging data shown cetuximab in 
radiotherapy may not be preferable for HPV positive cancers
119,120
. 
Nevertheless, the optimal treatment for HPV positive HNSCC patients 
remains uncertain. HPV positive cancers appear more sensitive to 
chemoradiation as patients with low risk HPV positive oropharyngeal cancers 
have almost double the overall survival as patients with high risk HPV 
negative cancers. This benefit in HPV positive patients results from improved 
locoregional control rather than decreased distant metastasis.  
Trans-oral surgery is evolving as a feasible treatment option for early 
stage Squamous cell carcinoma of the oropharynx. Nominally invasive trans-
oral surgery can be performed by transoral laser microsurgery or trans-oral 
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robotic surgery. The benefits of minimally invasive trans-oral surgery include 
low morbidity and mortality and good functional outcomes
121
.  
Prevention of HPV- Positive Head and Neck Squamous Cell Carcinomas 
Cancer may arise due to mutations or from exposure to environmental 
factors. As cancers are quite heterogeneous in nature, with a multitude of 
mutations, identifying therapies that work on entire tumor cell populations 
including tumor-initiating or cancer stem cells has been difficult. Current 
management procedures such as surgery, radiation, chemotherapy which 
impact the quality of life of the patients. The changing ability of human 
papillomavirus in the cervix, anogenital tract, and oropharynx suggests that 
prevention of HPV infection may ultimately prevent HPV associated cervical 
and head and neck cancers. 
Gardasil and Cervarix vaccines are used to prevent most common 
oncogenic HPV types known to cause cervical cancer. High risk HPV 16 and 
HPV 18 is prevented by Cervarix a bivalent vaccine, Gardasil is a 
quadrivalent which protects against HPV 16 and HPV 18 as well as the low 
risk HPV 6 and HPV 11 types
122,123
. United States Food and Drug 
Administration (FDA) recommend vaccination for men and women, between 
the ages of 9-26 years. HPV infection most likely occurs during this age 
group. It is important to begin vaccination at the earliest recommended ages, 
before the start of sexual activity to get maximum protection against HPV 
infection. Vaccination after the HPV infection does not result in increased 
protection from the virus or clearance of it. These vaccines utilize virus-like 
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particles (VLP) formed by self-assembly of the HPV capsid protein L1 to 
elicit the immune response, as opposed to live or attenuated virus. Antibodies 
are then produced against the L1-specific to each HPV type included in the 
vaccine
124
.  
These vaccines are protective against cervical, vaginal and vulvar 
cancers and also genital warts. These vaccines are not yet approved by U.S.  
F.D.A. for HPV infected HNSCCs. This is due to the lack of detailed 
information on HPV associated HNSCCs required by the F.D.A.  As more 
than 90% of all HNSCCs are HPV 16, these vaccines may be highly 
efficacious. Use of currently available vaccines following development of 
cancer, do not provide clinical benefit, because expression of the capsid 
proteins is lost during transformation. Oncologists can advocate universal 
HPV vaccination for both boys and girls, a recommendation shared by CDC 
(Centers for Disease Control and Prevention) and American Academy of 
Pediatrics. 
 
Table 4. Differences between Prophylactic and Therapeutic Vaccines 
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Future directions 
Many groups are doing research to better understand the biology of 
HPV- Positive HNSCC, to improve prevention, screening, diagnosis and 
identify and validate novel therapeutic targets. 
Till now limited information is available about the natural history of 
oral HPV infection.   
Further longitudinal research is needed to better understand the 
transmission of oral HPV infection, clearance and persistence of the infection.  
Similar to cervical cancer, persistence of HPV infection may likely prove 
central for HPV positive HNSCC. 
Prophylactic HPV vaccines are having high efficacy for the prevention 
of anal, cervical, vaginal and vulvar cancer development among those 
individuals who are not previously exposed to HPV infection.   
Direct evaluation of vaccine efficacy against head and neck HPV 
infection and tumor development is still necessary as there are no published 
data on this topic.  
HPV vaccination as a public health measure against anogenital HPV 
infection will most probably also have a favorable impact on the frequency of 
HPV associated HNSCCs.  
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Biomarker detection in saliva seems to be promising for secondary 
prevention. 
The incorporation of new screening method like HPV detection in oral 
fluid into the current diagnostic methods will help in early detection and 
intervention, risk assessment and response to treatment of HNSCC. 
Further research has the potential for the development of a screening 
test similar to Papanicolaou test, which could be used to screen individuals at 
high risk for developing HPV-associated HNSCC. 
HPV-positive HNSCC, after treatment has to be monitored for 
detection of disease persistence or early disease recurrence. 
Salivary rinsing as a possible screening test for recurrence of HPV 
positive tumors, after treatment has been evaluated. In a study with small 
number of persons, detection of E6 and E7 copy number by RT-PCR from 
salivary rinses had a specificity of 50% and sensitivity of 100%. for detection 
of oropharyngeal cancer recurrence.  
However, larger study is needed to determine the value of salivary 
rinsing as a screening test for tumor recurrence.  
In the next few years, we will likely to use HPV tumor status not only 
for prognostic purpose, but also for selection of treatment approaches.  
Further studies will help in implementation of de-escalation of 
treatment intensity in HPV-Positive HNSCC. 
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In the near future we may employ significantly different treatments for 
patients with HPV-positive as compared to HPV negative HNSCC.  
Understanding the biology of HPV positive HNSCCs at the molecular 
level, will provide the ability to rationally personalize therapy to improve 
therapeutic outcomes. 
In the near future, targeted therapy for HPV associated HNSCCs will 
become possible.   
The most important trials going on for targeted therapy are, 
Extracellular blocking of HER/EGFR, Monoclonal antibodies against EGFR, 
Intracellular blocking of HER/EGFR network etc. 
Immunotherapies targeting HPV E6 and E7 oncoproteins are being 
developed which will be of benefit in HPV associated Head and neck 
squamous cell carcinomas. 
TNM Staging of Carcinoma of the Oropharynx and Hypopharynx 
Primary tumor (T) 
TX Primary tumor cannot be assessed  
T0 No evidence of primary tumor 
TIS Carcinoma in situ 
Oropharynx 
T1 Tumor 2 cm or less in greatest dimension 
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T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension 
T3 Tumor more than 4 cm in greatest dimension or extension to lingual 
 surface of epiglottis. 
T4a Moderately advanced local disease  
Tumor invades the larynx, extrinsic muscle of tongue, medial 
 pterygoid, hard palate, or mandible 
T4b Very advanced local disease 
Tumor invades lateral pterygoid muscle, pterygoid plates, lateral 
 nasopharynx, or skull base, or encases carotid artery. 
Hypopharynx 
T1 Tumor limited to one subsite of hypopharynx and/or 2 cm or less in 
 greatest dimension 
T2 Tumor invades more than one subsite of hypopharynx or an adjacent 
site, or measures more than 2 cm in greatest dimension without fixation 
of hemilarynx. 
T3 Tumor more than 4 cm in greatest dimension or with fixation of 
hemilarynx or extension to esophagus. 
T4a Moderately advanced local disease 
Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or 
central compartment soft tissue 
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T4b Very advanced local disease 
Tumor invades prevertebral fascia, encases carotid artery, or invades 
mediastinal structures. 
Regional Lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest 
dimension.  
N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension,  or in multiple ipsilateral lymph 
nodes, none  more than 6 cm in greatest dimension, or in bilateral or 
contralateral lymph nodes, none  more than 6 cm in greatest dimension. 
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension. 
N2b Metastasis in multiple ipsilateral lymph nodes, none  more than 6 cm in 
greatest dimension. 
N2c Metastasis in bilateral or contralateral lymph nodes, none  more than 6 
cm in greatest dimension. 
N3 Metastasis in a lymph node, more than 6 cm in greatest dimension 
Distant Metastasis (M) 
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M0 No distant metastasis 
M1 Distant metastasis 
Anatomic Stage / Prognostic groups 
Stage 0 TISN0M0 
Stage I T1N0M0 
Stage II T2N0M0 
Stage III T3N0M0 
  T1N1M0 
  T2N1M0 
  T3N1M0 
Stage IVA T4aN0M0 
  T4aN1M0 
  T1N2M0 
  T2N2M0 
 T3N2M0 
 T4aN2M0 
Stage IVB T4b  Any N  M0 
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 Any T N3 M0 
Stage IVC Any T AnyN M1 
TNM Staging of Carcinoma of the Larynx 
Primary tumor (T) 
TX Primary tumor cannot be assessed  
T0 No evidence of primary tumor 
TIS Carcinoma in situ 
Supraglottis 
T1 Tumor limited to one subsite of supraglottis with normal vocal cord 
mobility 
T2 Tumor invades mucosa of more than one adjacent subsite of 
supraglottis or glottis or region outside the supraglottis (e.g. mucosa of  
base of tongue, vallecula, medial wall of pyriform sinus) without 
fixation of the larynx. 
T3 Tumor limited to larynx with vocal cord fixation and/or invades any of 
the following: post cricoids area, pre-epiglottic tissues, paraglottic 
space, and or minor thyroid cartilage erosion (e.g. inner cortex) 
T4a Moderately advanced local disease 
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Tumor invades through the thyroid cartilage and/or invades tissues 
beyond the larynx (e.g. trachea, soft tissues of neck including deep 
extrinsic muscle of the tongue, strap muscles, thyroid or esophagus) 
T4b Very advanced local disease 
Tumor invades prevertebral space, encases carotid artery, or invades 
mediastinal structures. 
Glottis 
T1 Tumor limited to the vocal cord(s) (may involve anterior or posterior 
commissure) with normal mobility. 
T1a Tumor limited to one vocal cord 
T1b Tumor involves both vocal cords 
T2 Tumor extends to supraglottis and/or subglottis, or with impaired vocal 
cord mobility. 
T3 Tumor limited to larynx with vocal cord fixation, and/or invade 
paraglottic space and/or minor thyroid cartilage erosion (e.g. inner 
cortex) 
T4a Moderately advanced local disease 
Tumor invades through the thyroid cartilage and/or invades tissues 
beyond the larynx (e.g. trachea, soft tissues of neck including deep 
extrinsic muscle of the tongue, strap muscles, thyroid or esophagus) 
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T4b Very advanced local disease 
Tumor invades prevertebral space, encases carotid artery, or invades 
mediastinal structures. 
Subglottis 
T1 Tumor limited to the subglottis 
T2 Tumor extends to vocal cord(s) with normal or impaired mobility 
T3 Tumor limited to larynx with vocal cord fixation 
T4a Moderately advanced local disease 
Tumor invades cricoid or  thyroid cartilage and/or invades tissues 
beyond the larynx (e.g. trachea, soft tissues of neck including deep 
extrinsic muscle of the tongue, strap muscles, thyroid or esophagus) 
T4b Very advanced local disease 
Tumor invades prevertebral space, encases carotid artery, or invades 
mediastinal structures. 
Regional Lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest 
dimension.  
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N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension,  or in multiple ipsilateral lymph 
nodes, none  more than 6 cm in greatest dimension, or in bilateral or 
contralateral lymph nodes, none  more than 6 cm in greatest dimension. 
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension. 
N2b Metastasis in multiple ipsilateral lymph nodes, none  more than 6 cm in 
greatest dimension. 
N2c Metastasis in bilateral or contralateral lymph nodes, none  more than 6 
cm in greatest dimension. 
N3 Metastasis in a lymph node, more than 6 cm in greatest dimension 
Distant Metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
Anatomic Stage / Prognostic groups 
Stage 0 TISN0M0 
Stage I T1N0M0 
Stage II T2N0M0 
Stage III T3N0M0 
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  T1N1M0 
  T2N1M0 
 T3N1M0 
Stage IVA T4aN0M0 
 T4aN1M0 
 T1N2M0 
 T2N2M0 
 T3N2M0 
 T4aN2M0 
Stage IVB T4b  Any N  M0 
 Any T N3 M0 
Stage IVC Any T AnyN M1 
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MATERIALS AND METHODS 
Study Place: 
Department of Pathology, Chengalpattu Medical College and Hospital, 
Chengalpattu. 
Study Design: 
The present cross-sectional study was a prospective study conducted in 
the Department of Pathology during the period of June 2014 to August 2015 . 
Ethical clearance for the study was obtained from the Institutional Ethics 
Committee of Chengalpattu Medical College, Chengalpattu. 
A total sample of 60 cases of HNSCC were analyzed during the period 
of June 2014 to August 2015. 
Study Population 
Inclusion Criteria 
Tissue blocks of patients who are diagnosed as Oropharyngeal and 
Upper Respiratory Tract squamous cell carcinoma by biopsy.    
Exclusion Criteria: 
Tissue blocks of patients who are diagnosed as Oropharyngeal and 
Upper Respiratory Tract squamous cell carcinoma by biopsy and underwent 
Radiotherapy or Chemotherapy.    
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During the period of June 2014 to August 2015, as per the inclusion 
and exclusion criteria, biopsies received in the Department of  Pathology were 
included. History written in the histopathology request form were recorded on 
predesigned and pretested proforma (Annexure I). 
MATERIALS USED 
Tissue sections prepared from paraffin embedded formalin fixed tissues  
Haematoxylin and eosin staining kit 
p16
INK4a
 monoclonal antibody kit 
Positive control 
Negative control 
Method: 
 Blocks and slides of 60 patients in which histopathological examination of 
hematoxylin and eosin stained sections of biopsy from Oropharyngeal and 
Upper Respiratory Tract sites confirmed as squamous cell carcinoma were 
taken up for the study.   
 Immunohistochemistry was performed on the tissue sections taken from 
the blocks of the cases confirmed as squamous cell carcinoma.  
Immunohistochemistry Procedure 
1. 4μ thick sections were cut from formalin fixed paraffin embedded 
tissue samples and transferred to gelatin-chrome alum coated slides.  
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2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. Rehydrated through descending grades of alcohol as follows : 
Absolute alcohol x 2 changes 5 minutes each 
90% alcohol x 5 minutes 
Washed in distilled water 2 changes, 2 minutes each  
5. Heat induced antigen retrieval was done with microwave oven at 150 
degree celsius with citrate buffer (pH 6.0) for 15 to 20 minutes. 
6. Then cooled for 10 minutes. 
7. Washed in distilled water 2 changes, 2 minutes each. 
8. Washed in TBS for 2 minutes. 
9. Endoperoxidase blocking was done by adding hydrogen peroxide on 
the section and kept for 5 minutes. 
10. Washed in the wash buffer for 2 minutes twice. 
11. Primary antibody p16INK4a (Mouse monoclonal, Clone (G175-405) ; 
prediluted) was added and kept for 30 minutes in a moist chamber. 
12. Then washed in wash buffer 2 minutes 2 times each. 
13. Poly excel target binder reagent was added and kept for 15 minutes. 
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14. Washed in two changes of buffer 2 minutes each. 
15. Poly excel HRP (Horse Radish Peroxidase) was added and incubated 
for 15 minutes. 
16. Washed with buffer – 2 minutes, 2 changes.  
17. Working DAB chromogen (1ml DAB buffer + 1 drop chromogen, mix 
well) was added and kept for 2-5 minutes. 
18. Then washed in distilled water. 
19. Counter stained with hematoxylin for 30 seconds. 
20. The slides were washed in running tap water for 3 minutes.  
21. The slides were air dried, cleared with xylene and mounted with DPX.  
 Positive control included block sections of known p16INK4a positive 
cases. 
 Negative control included Primary antibody  replaced with PBS and 
normal oral tissue. 
 Immunostained sections were reviewed and a strong nuclear as well as 
cytoplasmic staining was considered as positive reaction, as described 
by Klaes et al
125
.,   
 Distribution of p16INK4a positivity were scored as negative (<1% cells 
positive), sporadic   (<5% cells positive), focal (<25% cells positive) 
and diffuse (>25% cells positive). 
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Data Collection 
H &E stained sections and immunostained sections were assessed using 
light microscope. 
Observations: 
History   :  Smoking/Alcohol 
Site of the lesion  : 
Histopathological confirmation and grading of H&E stained section :  
HNSCC Grade 1 
HNSCC Grade 2 
HNSCC Grade 3 
p16
INK4a 
 expression 
Negative   
(<1% cells positive)*  
Positive 
Sporadic (<5% cells positive)*   
Focal (<25% cells positive)* 
 Diffuse (>25% cells positive)* 
*As described by Klaes et al
125
 .   
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Statistical analysis: 
Datas obtained were coded and entered into the Microsoft excel spread 
sheet (Annexure II). Datas were compared between groups using Pearson Chi-
square or Fisher‘s exact tests (p<0.05). All statistical analysis were performed 
using SPSS statistical software version 11. Charts were prepared using 
Microsoft excel 2007. 
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OBSERVATION AND RESULTS 
In the present study 75% of the cases of HNSCC were above 50 years 
of age (Table 5.). However none of the cases were observed below 22 years of 
age (Table 6.). The beginning age for p16
INK4a
 positive HNSCC cases in our 
study is 22 years and is 44 years for p16
INK4a
 negative cases. Among the 15 
HNSCC cases below 50 years of age, 14 cases (93.33%) were p16
INK4a
 
positive. Among the HNSCC cases above 50 years of age 93.33% were 
positive for p16
INK4a
. The range of the age group is much wider in the p16
INK4a
 
positive cases. There is no difference in the mean age among the HNSCC 
p16
INK4a
 positive and negative groups. The median age for p16
INK4a
 negative 
cases is slightly lower (58 years) 
Age 
group 
(years) 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve  
n=56 
P16
INK4a
-ve  
n=4 P value 
n % n % 
Age≤50 15 14 93.33 1 6.67 
1.000 
Age>50 45 42 93.33 3 6.67 
Fisher‘s exact test 
Table 5.  Age distribution of patients with HNSCC 
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Table 6.  Age distribution of patients with HNSCC 
In the sex distribution 85% of the HNSCC cases were male and 15% of 
the cases were female (Table 7.). All the female cases 15 (100%) were 
p16
INK4a
 positive. 47/51 male cases (92.16%) were p16
INK4a
 positive. 5/9 
female cases are ≤50 years and all are p16INK4a positive. 10/51 male cases are 
≤50 years and 90% of which are p16INK4a positive. There is no much 
difference between p16
INK4a
 positive cases in the ≤50 years and >50 years age 
groups (Table 8.). 
Gender 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 P value 
n % n % 
Male 51 47 92.16 4 7.84 
1.000 
Female 9 9 100 0 0 
Fisher‘s exact test 
Table 7.  Sex distribution of patients with HNSCC 
Age 
group 
(years) 
HNSCC 
All patients 
n=60 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
Range 22-83 22-83 44-75 
Mean±SD 58.68±12.83 58.68±12.94 58.75±12.91 
Median 60 60 58 
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Table 8.  Sex distribution of patients with HNSCC in relation to age. 
Gender 
Total 
=60 
HNSCC 
Age≤50 years Age>50 years 
Total 
=15 
P16
INK4a
 
+ve 
n=14 
P16
INK4a
  
-ve 
n=1 P 
value 
Total=
45 
P16
INK4a 
+ve 
 n=42 
P16
INK4a
    
-ve 
n=3 P 
value 
n % n % n % n % 
Male 51 10 9 90 1 10 1.000 41 38 92.68 3 7.32 1.000 
Female 9 5 5 100 0 0 4 4 100 0 0 
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Oropharynx was the most common site involved in the HNSCC (30%), 
followed by oral cavity, hypopharynx and larynx(Table 9, Chart 6). In our 
study we did not receive biopsy from nasopharynx. The percentage of p16
INK4a
 
negative cases were similar in the different sites of HNSCC. 
Site of the 
lesion 
 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 P value 
n % n % 
Oral cavity 17 16 94.12 1 5.88 
0.988 
Oropharynx 18 17 94.44 1 5.56 
Hypopharynx 13 12 92.30 1 7.70 
Larynx 12 11 91.67 1 8.33 
Total 60 56 93.33 4 6.67  
Pearson Chi Square test 
Table 9.  Distribution of patients with HNSCC in different sites of              
Head and Neck region 
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Comparing the oropharyngeal and non-oropharyngeal squamous cell 
carcinomas, p16
INK4a
 positive cases are 94.44% in the oropharyngeal cases and 
it is 92.86% in the non-oropharyngeal cases. (1.58% higher in the 
oropharyngeal squamous cell carcinomas) (Table 10.). 
 
Site of the lesion 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 P 
value 
n % n % 
Oropharyngeal 18 17 94.44 1 5.56 
1.000 
Non-oropharyngeal 42 39 92.86 3 7.14 
Fisher‘s exact test 
Table 10.  Distribution of patients with HNSCC in Oropharyngeal and 
Non-oropharyngeal region 
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Among the oral cavity squamous cell carcinomas, tongue was the most 
common site involved (64%), followed by buccal mucosa, soft palate, alveolus 
and gingiva. 90.91% of the tongue squamous cell carcinomas are p16
INK4a
 
positive (Chart 8.).   
Site of 
the lesion 
Total 
n=17 
Oral cavity SCC 
P16
INK4a
  +ve 
n=16 
P16
INK4a
     -ve 
n=1 P value 
n % n % 
Tongue 11 10 90.91 1 9.09 
0.965 
Buccal 
mucosa 
2 2 100 0 0 
Alveolus 1 1 100 0 0 
Soft 
palate 
2 2 100 0 0 
Gingiva 1 1 100 0 0 
Pearson Chi Square test 
Table 11.  Distribution of sites with SCC of Oral cavity 
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Majority of HNSCC cases in our study were of grade 2 (35/60 cases; 
58% ), followed by grade 1 (24/60 cases; 39%) and grade 3 (2/60; 3%) on the 
histopathological grading after Haematoxylin and Eosin staining (Table 12, 
Chart 9). 
Tumour 
differentiation 
Total 
n=60 
P16
INK4a
  +ve 
n=56 
P16
INK4a
   -ve 
n=4 P value 
n % n % 
HNSCC Grade1 23 22 95.65 1 4.35 
0.761 HNSCC Grade2 35 32 91.43 3 8.57 
HNSCC Grade3 2 2 100 0 0 
Pearson Chi Square test 
Table 12.  p16
INK4a
  expression in different grades of HNSCC 
 
 
 
82 
 
While observing the level of expression of p16
INK4a
 by IHC, 93.33% 
cases of HNSCC were found to be positive (Table 9.). On observing the level 
of expression of p16
INK4a
 in HNSCC, out of 60 cases 53.33% had diffuse 
pattern, followed by focal (23.33%) and sporadic (16.67%) (Table 13, Chart 
10). 
Further, out of the 32/60 cases having diffuse pattern of p16
INK4a
 
expression, 56.52% of grade 1, 51.43% of grade 2 and 50% of grade 3 
HNSCC cases had diffuse pattern. Sporadic pattern of expression of p16
INK4a
 
was observed in 21.74%, 11.43% and 50% of cases among the HNSCC grade 
1, grade 2 and grade 3 respectively (Table 13.). 
Lesions 
Total 
n=60 
Negative 
n=4 
Sporadic 
n=10 
Focal 
n=14 
Diffuse 
n=32 
P 
value 
n % n % n % n % 
HNSCC  
Grade 1 
23 1 4.35 5 21.74 4 17.39 13 56.52 
0.667 
HNSCC  
Grade 2 
35 3 8.57 4 11.43 10 28.57 18 51.43 
HNSCC  
Grade 3 
2 0 0 1 50 0 0 1 50 
Total 60 4 6.67 10 16.67 14 23.33 32 53.33  
Pearson Chi Square test 
Table 13.  Level of p16
INK4a
  expression in different grades of HNSCC 
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Among the 60 cases of HNSCC 44 cases (68%) had smoking history. 
Among the patients with smoking history 92.8% are p16
INK4a
 positive (Table 
14.).      
Fisher‘s exact test 
Table 14. Distribution of patients with smoking in HNSCC 
 
Smoking 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
 
P value 
n % n % 
Yes 41 38 92.68 3 7.32 1.000 
No 19 18 94.74 1 5.26 
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Out of the 60 cases of HNSCC 7 cases (12%) had alcohol consumption  
history. Among the patients with alcohol consumption history 85.71% are 
p16
INK4a
 positive (Table 15.).    
Fisher‘s exact test 
Table 15. Distribution of patients with alcohol in HNSCC 
Alcohol 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
 
P value 
n % n % 
Yes 7 6 85.71 1 14.29 0.399 
No 53 50 94.34 3 5.66 
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COLOUR PLATES 
 
Fig. 1. WDSCC Well differentiated squamous cell carcinoma                      
(WDSCC) – H&E staining (x100) 
 
Fig. 2.  Moderately differentiated squamous cell carcinoma (MDSCC) -             
H&E staining (x100) 
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Fig. 3.  Poorly differentiated squamous cell carcinoma (PDSCC)- H&E 
staining (x100) 
 
Fig. 4. WDSCC – Diffuse pattern of p16INK4a immunostaining (x400) 
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Fig. 5. MDSCC – Diffuse pattern of p16INK4a immunostaining (x400) 
 
Fig. 6. PDSCC – Diffuse pattern of p16INK4a immunostaining (x400) 
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Fig. 7. WDSCC – Focal pattern of p16INK4a immunostaining (x400) 
 
Fig. 8. MDSCC – Focal pattern of p16INK4a immunostaining (x400) 
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Fig. 9. WDSCC – Sporadic pattern of p16INK4a immunostaining (x400) 
 
Fig. 10. MDSCC – Sporadic pattern of p16INK4a immunostaining (x400) 
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Fig. 11. PDSCC – Sporadic pattern of p16INK4a immunostaining (x400) 
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DISCUSSION 
HNSCC continues to be a public health problem with an estimated 
incidence of 600 000  cases and 200 000 deaths annually
1
.  
In the present study, oropharynx was observed to be the commonest site 
affected by squamous cell carcinoma. Larynx was observed to be the least 
affected site. 
The reports implicating specific HPV types in HNSCC were first 
published in 1985
126,127
. It has been observed that HPV 16 participates in 
disruption of regulation of p16
INK4a
 suppressor protein and its over expression 
can be used as a surrogate marker for detection of HPV association in 
HNSCC. It has been observed that there are two groups of HNSCC, one group 
is associated with HPV infection (p16
INK4a
 positive) and the other group is not 
associated with HPV infection (p16
INK4a
 negative). In the HPV associated 
HNSCC two different mechanisms at the molecular level produce 
carcinogenesis via p53 and pRB
60
. The present study also indicates two groups 
of HNSCC on the basis of p16
INK4a
 expression as 93.33% cases of HNSCC 
were positive for the over expression of p16
INK4a
. 
Further it has been observed that p16
INK4a
 expression is a strong 
independent prognostic indicator also
114
. Patients with HNSCC not expressing 
p16
INK4a
 had increased risk of death and increased risk of recurring cancer in 
comparison to those expressing it. Prognosis of p16
INK4a
 positive cases has 
been reported to be better irrespective of histological grade. 
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Our study is a hospital based study and there is an increase in the 
percentage of p16
INK4a
 positive HNSCC cases. According to Caihua Liang et 
al 2012, the prevalence of HNSCC based on PCR and p16
INK4a
 detection based 
studies was 62%
128
.   
In the present study 75% of the cases are more than 50 years of age. 
According to Zeyi Deng et al 2014 86.67% cases are more than 50 years of 
age
129
. 
In  the present study, among the 15 cases (25%) which are less than 50 
years of age, 93.33% are p16
INK4a
 positive. According to Zeyi Deng et al 2014 
35% are p16
INK4a
 positive
129
 (Table 16.). 
Our 
study 
 
Age 
group 
(years) 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
 
P value 
n % n % 
Age≤50 15 14 93.33 1 6.67 
1.000 
Age>50 45 42 93.33 3 6.67 
Zeyi 
Deng et 
al 2014 
Age 
group 
(years) 
Total 
n=150 
HNSCC 
P16
INK4a
  +ve 
n=30 
P16
INK4a
  -ve 
n=120 
 
P value 
n % n % 
Age≤50 20 7 35 13 65 
0.128 
Age>50 130 23 17.7 107 82.3 
Table 16.  Age distribution of patients with HNSCC - Comparison 
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The mean age for p16
INK4a
 positive HNSCC cases in our study is 58.68 
years. According to Zeyi Deng et al 2014 it is 61.8 years
129
 and according to 
Caihua Liang et al 2012 it is56.4 years
128 
(Table 17.). 
The median age for p16
INK4a
 positive and negative HNSCC cases in our 
study are 60 years and 58 years respectively. According to Gul Kanyilmaz et 
al 2015 it is 60 and 59 years respectively
130
. 
The Range of the age group for p16
INK4a
 positive HNSCC cases in our 
study is 22 to 83 years. According to Gul Kanyilmaz et al 2015 it is 15 to 70 
years
130
. According to Zeyi Deng et al 2014 it is 39 to 89 years
129
 (Table 17.). 
In our study, the beginning age in the p16
INK4a
 positive HNSCC cases is 
22 years. According to Gul Kanyilmaz et al 2015 it is 15 years
130
. According 
to Zeyi Deng et al 2014 it is 39 years
129
. 
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Table 17.  Age distribution of patients with HNSCC - Comparison 
In our study, male cases among the total HNSCC cases is 85%. 
According to Gul Kanyilmaz et al 2015 it is 88.55%
130
. According to Zeyi 
Deng et al 2014 it is 84.67%
129
. According to Caihua Liang et al 2012 it is 
71.24%
128
 (Table 18.). 
Our study 
Age 
group 
(years) 
HNSCC 
All patients 
n=60 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
Range 22-83 22-83 44-75 
Mean±SD 58.68±12.83 58.68±12.94 58.75±12.91 
Median 60 60 58 
Zeyi Deng 
et al 2014 
Age 
group 
(years) 
HNSCC 
All patients 
n=150 
P16
INK4a
  +ve 
n=30 
P16
INK4a
  -ve 
n=120 
Range 28-89 39-89 28-86 
Mean 64.1 61.8 64.7 
Gul 
Kanyilmaz 
et al 2015 
 
Age 
group 
(years) 
HNSCC 
All patients 
n=131 
P16
INK4a
  +ve 
n=58 
P16
INK4a
  -ve 
n=73 
Range 15-82 15-70 17-82 
Median 60 60 59 
Caihua 
Liang et al 
2012 
Age 
group 
(years) 
HNSCC 
P16
INK4a
  +ve 
n=54 
P16
INK4a
  -ve 
n=179 
Mean±SD 56.4±9.2 60.3±12.3 
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In our study, among the male patients 92.16% and among the female 
patients 100% are p16
INK4a
 positive. According to Gul Kanyilmaz et al 2015 
40.52% male patients and 73.33% female patients are p16
INK4a
 positive
130
.  
According to Zeyi Deng et al 2014 18.9% male patients and 26.1% female 
patients are p16
INK4a
 positive
129
. According to Caihua Liang et al 2012 27.7% 
male patients and 11.9% female patients are p16
INK4a
 positive
128
. 
Our study 
 
Gender 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
 
P 
value n % n % 
Male 51 47 92.16 4 7.84 
1.000 
Female 9 9 100 0 0 
Gul 
Kanyilmaz 
et al 2015 
 
 
Gender 
Total 
n=131 
HNSCC 
P16
INK4a
  +ve 
n=58 
P16
INK4a
  -ve 
n=73 
 
P 
value n % n % 
Male 116 47 82 69 95 
0.01 
Female 15 11 18 4 5 
Zeyi Deng 
et al 2014 
 
Gender 
Total 
n=150 
HNSCC 
P16
INK4a
  +ve 
n=30 
P16
INK4a
  -ve 
n=120 
 
P 
value n % n % 
Male 127 24 18.9 103 81.1 
0.408 
Female 23 6 26.1 17 73.9 
Caihua 
Liang et al 
2012 
 
Gender 
Total 
n=233 
HNSCC 
P16
INK4a
  +ve 
n=54 
P16
INK4a
  -ve 
n=179 
 
P 
value n % n % 
Male 166 46 27.7 120 72.3 
0.01 
Female 67 8 11.9 59 88.1 
Table 18.  Sex distribution of patients with HNSCC - Comparison 
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In our study, 5/9 female cases are ≤50 years and all are p16INK4a 
positive. 10/51 male cases are ≤50 years and 90% of which are p16INK4a 
positive. There is no much difference between p16
INK4a
 positive cases in the 
≤50 years and >50 years age groups (Table 8.). 
In our study, the commonest site of the HNSCC oropharynx and the 
least common site is the nasopharynx. We did not receive biopsy from the 
nasopharynx during our study period. According to Zeyi Deng et al 2014 also 
the commonest site is the oropharynx and the least common site is the 
nasopharynx
129
 (Table 19.). 
In our study, the percentage of p16
INK4a
 positive cases is highest 
(94.44%) in the oropharynx and lowest (91.67%) in the larynx. (No biopsy 
received from the nasopharynx). According to Zeyi Deng et al 2014, highest 
(37.7%) in the oropharynx and lowest (7.7%) in the hypopharynx
129
. 
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Our study 
Site of the 
lesion 
 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
P 
value 
n % n % 
Oral cavity 17 16 94.12 1 5.88 
0.988 
Oropharynx 18 17 94.44 1 5.56 
Hypopharynx 13 12 92.30 1 7.70 
Larynx 12 11 91.67 1 8.33 
Total 60 56 93.33 4 6.67  
Zeyi Deng 
et al 2014 
Site of the 
lesion 
 
Total 
n=150 
HNSCC 
P16
INK4a
  +ve 
n=30 
P16
INK4a
  -ve 
n=120 
P 
value 
n % n % 
Oral cavity 24 2 8.3 22 91.7 
0.002 
Nasopharynx 10 2 20 8 80 
Oropharynx 53 20 37.7 33 62.3 
Hypopharynx 39 3 7.7 36 92.3 
Larynx 24 3 12.5 21 87.5 
Total 150 30 20 120 80  
Table 19.  Distribution of patients with HNSCC in different sites of Head 
and Neck region - Comparison 
In our study, the percentage of p16
INK4a
 positive cases in the 
oropharyngeal group is 94.44% (higher) and in the non-oropharyngeal group 
is 92.86% (lower). According to Zeyi Deng et al 2014, also higher (37.74%) in 
the oropharyngeal group and lower (10.31%) in the non-oropharyngeal 
group
129
 (Table 20.). 
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Our study 
Site of the lesion 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
n % n % 
Oropharyngeal 18 17 94.44 1 5.56 
Non-
oropharyngeal 
42 39 92.86 3 7.14 
Zeyi Deng 
et al 2014 
Site of the lesion 
Total 
n=150 
HNSCC 
P16
INK4a
  +ve 
n=30 
P16
INK4a
  -ve 
n=120 
n % n % 
Oropharyngeal 53 20 37.74 33 62.26 
Non-
oropharyngeal 
97 10 10.31 87 89.69 
Table 20.  Distribution of patients with HNSCC in Oropharyngeal and 
Non-oropharyngeal region - Comparison 
In our study, in the oral cavity squamous cell carcinoma, the most 
common site involved is tongue (64%) and the least common site involved is 
the alveolus and gingiva (each 6%). According to Pradyot Prakash et al 2013 
the most common site is the tongue (37.7%) and the least common site is the 
hard palate and gingiva (each 1.45%)
131
 (Table 21).  
In our study, 90.91% of tongue squamous cell carcinomas were 
p16
INK4a
 positive (Table 11.). 
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Site of the 
lesion 
Oral cavity SCC 
Our study 
n=17 
Pradyot Prakash et al 2013 
n=69 
n % n % 
Tongue 11 64 26 37.7 
Buccal 
mucosa 
2 12 17 24.6 
Cheek 0 0 13 18.8 
Alveolus 1 6 4 5.8 
Lip 0 0 2 2.9 
Angle of 
mouth 
0 0 2 2.9 
Soft palate 2 12 3 4.3 
Hard palate 0 0 1 1.45 
Gingiva 1 6 1 1.45 
Table 21.  Distribution of sites with SCC of Oral cavity - Comparison 
In our study, p16
INK4a
 positive cases are highest (100%) in the grade 3 
HNSCC, followed by grade 1(95.65%) and lowest (91.43%) in the grade 2 
HNSCC. According to Zeyi Deng et al 2014, highest (42.1%) in the grade 1 
HNSCC, followed by grade 2(19%) and lowest (14.7%) in the grade 3 
HNSCC
129
 (Table 22.). 
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Our 
study 
Tumour 
differentiation 
Total 
n=60 
P16
INK4a
  +ve 
n=56 
P16
INK4a
   -ve 
n=4 
P 
value 
n % n % 
HNSCC  Grade 1 23 22 95.65 1 4.35 
0.761 HNSCC  Grade 2 35 32 91.43 3 8.57 
HNSCC  Grade 3 2 2 100 0 0 
Zeyi 
Deng et 
al 2014 
Tumour 
differentiation 
Total 
n=150 
P16
INK4a
  +ve 
n=30 
P16
INK4a
   -ve 
n=120 
P 
value 
n % n % 
HNSCC  Grade 1 19 8 42.1 11 57.9 
0.030 HNSCC  Grade 2 63 12 19 51 81 
HNSCC  Grade 3 68 10 14.7 58 85.3 
Table 22.  p16
INK4a
  expression in different grades of HNSCC - 
Comparison 
In our study, among the HNSCC cases, most (53.33%) are having 
diffuse pattern of p16
INK4a
 expression, followed by focal (23.33%) and lowest 
(16.67%) having sporadic pattern of expression. In our study, in the oral cavity 
squamous cell carcinoma, most (35.30%) are having diffuse pattern, followed 
by focal and sporadic patterns, each having 29.41%. According to Pradyot 
Prakash et al 2013,  in the oral cavity squamous cell carcinoma, diffuse pattern 
is the most common (31.9%), followed by sporadic (24.6%) and lowest 
(14.5%) having focal pattern of expression
131
 (Table 23.). 
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Our 
study 
Site 
of the 
lesion 
Oral cavity SCC 
Negative Sporadic Focal Diffuse 
n % n % n % n % 
Total   
n=17 
1 5.88 5 29.41 5 29.41 6 35.30 
Pradyot 
Prakash 
et al 
2013 
 
Site 
of the 
lesion 
Oral cavity SCC 
Negative Sporadic Focal Diffuse 
n % n % n % n % 
Total   
n=69 
20 29 17 24.6 10 14.5 22 31.9 
Table 23.  Level of p16
INK4a
  expression in Oral cavity SCC - Comparison 
In our study, among the p16
INK4a
 positive HNSCC cases 92.68% were 
having smoking habit. According to Gul Kanyilmaz et al 2015 45.92% of 
p16
INK4a
 positive cases were having smoking habit
130
.   According to Caihua 
Liang et al 2012 19.2% were having smoking habit
128
 (Table 24.). 
 
 
 
 
 
 
 
103 
 
Our study 
 
Smoking 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
 
P 
value n % n % 
Yes 41 38 92.68 3 7.32 
1.000 
No 19 18 94.74 1 5.26 
Gul 
Kanyilmaz 
et al 2015 
 
 
Smoking 
Total 
n=131 
HNSCC 
P16
INK4a
  +ve 
n=58 
P16
INK4a
  -ve 
n=73 
 
P 
value n % n % 
Yes 98 45 77 53 72 
ns 
No 33 13 23 20 28 
Caihua 
Liang et al 
2012 
 
Smoking 
Total 
n=233 
HNSCC 
P16
INK4a
  +ve 
n=54 
P16
INK4a
  -ve 
n=179 
 
P 
value n % n % 
Yes 187 36 19.2 151 80.8 
<0.01 
No 46 18 39.1 28 60.9 
Table 24. Distribution of patients with smoking in HNSCC – Comparison  
ns – not significant 
In our study, among the p16
INK4a
 positive HNSCC cases 85.71% were 
having alcohol consuming habit. According to Gul Kanyilmaz et al 2015 
35.71% of p16
INK4a
 positive cases were having alcohol consuming habit
130
 
(Table 25.). 
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Our study 
 
Alcohol 
Total 
n=60 
HNSCC 
P16
INK4a
  +ve 
n=56 
P16
INK4a
  -ve 
n=4 
 
P 
value n % n % 
Yes 7 6 85.71 1 14.29 
0.399 
No 53 50 94.34 3 5.66 
Gul 
Kanyilmaz 
et al 2015 
 
 
Alcohol 
Total 
n=131 
HNSCC 
P16
INK4a
  +ve 
n=58 
P16
INK4a
  -ve 
n=73 
 
P 
value n % n % 
Yes 14 5 9 9 12 
ns 
No 117 53 91 64 88 
Table 25. Distribution of patients with alcohol in HNSCC - Comparison 
ns – not significant 
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SUMMARY 
The incidence of HPV associated HNSCC is increasing over the past 30 
years. It is a growing public health concern. It has been reported that tissues of 
HPV associated HNSCCs over express p16
INK4a
 . Therefore p16
INK4a
 is used as 
a surrogate marker to detect HPV associated HNSCC. Immunohistochemical 
detection of p16
INK4a
 is an easy and simple technique than molecular detection 
of HPVs. Hence we investigated the presence of p16
INK4a
 in HNSCCs. 
The objectives of our study are (1)To study the association of p16
INK4a
 
expression with HNSCC, thus with the HPV. (2)To compare the p16
INK4a
 
expression in different sites of the HNSCC. (3)To correlate the level of 
p16
INK4a
 expression with different grades of HNSCC. 
A total sample of 60 cases were analysed during the period of June 
2014 to August 2015. We performed IHC detection in sections of formalin 
fixed paraffin embedded tissue of HNSCC cases and correlated the various 
patterns of p16
INK4a
 positivity with respect to histopathological diagnosis.   
In the present study, increased number of HNSCC cases were seen 
overexpressing p16
INK4a
 (93.33%). Oropharynx was the most common site for 
p16
INK4a
 positivity in HNSCC cases (94.44%). Among the oral cavity SCC 
cases, tongue was the most common site involved (64%). Of the HNSCC 
cases, most cases (53.33%) had diffuse pattern of p16
INK4a
 overexpression. 
However, DNA detection based studies are needed to validate the utility of 
IHC detection of p16
INK4a
 as a surrogate marker for HPV associated HNSCC.       
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CONCLUSION 
The present cross-sectional study ―Detection of p16INK4a in 
Oropharyngeal and Upper Respiratory Tract Squamous Cell Carcinoma‖ was 
conducted in the Department of pathology from June 2014 to August 2015. 
The present study demonstrated increased association of p16
INK4a
 over 
expression in cases of HNSCC (93.33%). HNSCC was more common in 
males with male to female ratio of  6 : 1 . Oropharynx accounted for the most 
common site of occurrence of HNSCC(30%). Also oropharynx was the most 
common site for p16
INK4a
 positivity in HNSCC cases (94.44%). 
Among the oral cavity SCC cases, tongue was the most common site 
involved (64%). Among the p16
INK4a
 positive cases most cases are HNSCC 
Grade 2 (53%). Of the HNSCC cases, most cases (53.33%) had diffuse pattern 
of p16
INK4a
 over expression. Diffuse pattern of p16
INK4a
 over expression was 
most common in HNSCC Grade 1 cases (56.52%). 
Further, DNA detection based studies are needed to validate the utility 
of IHC detection of p16
INK4a
 as a surrogate marker for HPV associated 
HNSCC.   
In future, prophylactic vaccination for boys and girls before the starting 
of sexual activity will prevent HPV infection and thus reduce the incidence of 
HPV associated HNSCC. Plans to improve public awareness and knowledge 
of clinical features and risk factors will reduce the disease burden of HPV 
associated HNSCC.     
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ANNEXURE - I 
PROFORMA 
Date:   
1. Name     :         OP/IP No :                                                                             
2. Age         : 
3. Sex          :   Male  Female 
4. History  :    Smoking – Yes  /  No  Alcohol – Yes  /  No 
Clinical Diagnosis  : 
Site of the lesion  : 
Histopathological confirmation and grading of H&E stained section 
HNSCC Grade 1 
HNSCC Grade 2 
HNSCC Grade 3 
p16
INK4a 
 expression 
Negative 
Positive 
Sporadic 
Focal 
Diffuse
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MASTER  CHART 
S. 
No. 
Path No. Age 
Age 
group 
Sex 
Site -
HNSCC 
Site -oral 
SCC 
Clinical diagnosis 
HPE 
diag 
IHC 
diag 
Smoking Alcohol 
1 G220/14 57 2 1 4 0 Growth Supraglottis 2 3 1 2 
2 G227/14 57 2 1 1 5 Growth Gingiva 2 2 1 2 
3 G237/14 70 2 1 2 0 Growth Rt Tonsil 2 1 1 1 
4 G268/14 55 2 1 1 1 Growth Tongue 1 2 1 2 
5 G295/14 80 2 1 3 0 Growth Hypopharynx 1 0 1 2 
6 G310/14 49 1 1 2 0 Growth Oropharynx 1 3 1 2 
7 G329/14 52 2 1 2 0 Growth Oropharynx 2 0 1 2 
8 G389/14 52 2 1 3 0 Growth Lt Pyriform fossa 2 3 1 2 
9 G431/14 50 1 1 1 2 Growth Lt Buccal mucosa 1 1 1 2 
10 G527/14 52 2 1 1 1 Growth Tongue 1 1 1 1 
11 G528/14 54 2 1 2 0 Growth Oropharynx 1 1 2 2 
12 G529/14 80 2 1 4 0 Growth Supraglottis 2 1 2 2 
13 G652/14 45 1 1 1 1 Growth Tongue 2 2 1 2 
14 G665/14 63 2 1 3 0 Rt Pyriform fossa 1 3 2 2 
15 G788/14 50 1 1 2 0 Growth Rt Tonsil 1 2 1 2 
16 G802/14 67 2 1 1 1 Growth Tongue 2 3 2 2 
17 G920/14 67 2 1 1 1 Growth Tongue 1 3 1 2 
18 G922/14 75 2 1 2 0 Growth Tonsillar fossa 2 2 1 2 
19 G1000/14 60 2 1 2 0 Growth Oropharynx 1 1 2 2 
20 G1043/14 65 2 1 4 0 Transglottic growth 1 3 1 2 
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S. 
No. 
Path No. Age 
Age 
group 
Sex 
Site -
HNSCC 
Site -oral 
SCC 
Clinical diagnosis 
HPE 
diag 
IHC 
diag 
Smoking Alcohol 
21 G1046/14 60 2 1 1 1 ?Ca Tongue 2 2 1 2 
22 G1221/14 50 1 1 2 0 Growth Oropharynx 2 2 1 2 
23 G1286/14 55 2 1 2 0 Growth Lt Tonsil 1 3 1 2 
24 G1310/14 77 2 1 2 0 Growth Oropharynx 2 3 2 1 
25 G1538/14 22 1 2 4 0 Growth Vocal cord 2 2 2 2 
26 G1550/14 60 2 1 4 0 Growth Vocal cord 2 0 2 1 
27 G1587/14 65 2 2 3 0 Growth Rt Pyriform fossa 1 3 2 2 
28 G1597/14 65 2 1 3 0 Growth Lt Pyriform fossa 1 3 1 2 
29 G1736/14 75 2 1 4 0 Growth Supraglottis 2 2 1 2 
30 G1755/14 60 2 1 2 0 Growth Oropharynx 2 2 1 2 
31 G1763/14 23 1 2 2 0 Growth Oropharynx 2 3 2 2 
32 G1766/14 50 1 1 4 0 Growth Supraglottis 2 3 1 2 
33 G8/15 50 1 1 1 3 Growth Alveolus 2 1 1 2 
34 G47/15 44 1 1 1 1 ?Ca Tongue 2 0 1 2 
35 G68/15 63 2 1 3 0 Growth Hypopharynx 2 2 1 2 
36 G136/15 55 2 1 2 0 Growth Oropharynx 1 2 1 2 
37 G138/15 37 1 1 3 0 Growth Hypopharynx 1 3 2 2 
38 G187/15 58 2 1 3 0 ? Ca Hypopharynx 2 3 1 1 
39 G262/15 70 2 1 1 1 Growth Tongue 3 3 1 2 
40 G301/15 69 2 1 2 0 Growth Oropharynx 2 2 1 2 
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S. 
No. 
Path No. Age 
Age 
group 
Sex 
Site -
HNSCC 
Site -oral 
SCC 
Clinical diagnosis 
HPE 
diag 
IHC 
diag 
Smoking Alcohol 
41 G355/15 56 2 1 3 0 Growth Hypopharynx 2 3 1 2 
42 G470/15 65 2 1 3 0 Growth Hypopharynx 1 3 1 2 
43 G501/15 35 1 2 1 1 Ulcer Tongue 1 1 2 2 
44 G551/15 60 2 1 2 0 Growth Oropharynx 3 1 1 2 
45 G552/15 50 1 1 3 0 Growth Hypopharynx 2 3 1 2 
46 G588/15 40 1 2 1 2 ?Ca Rt Buccal vestibular 1 3 2 2 
47 G594/15 55 2 1 1 4 Ulcer Soft plalate 2 3 1 2 
48 G670/15 58 2 2 3 0 Growth Hypopharynx 2 3 2 2 
49 G676/15 79 2 2 1 4 Growth Solft palate 1 2 2 2 
50 G721/15 83 2 1 1 1 Ca Tongue 2 1 1 2 
51 G743/15 61 2 2 4 0 Growth Epiglottis 2 3 2 2 
52 G790/15 61 2 1 4 0 Growth Supraglottis 2 3 1 2 
53 G803/15 60 2 1 2 0 Growth Oropharynx 2 3 2 2 
54 G824/15 75 2 1 2 0 Growth Oropharynx 2 3 1 1 
55 G892/15 65 2 1 1 1 ? Ca Tongue 1 3 2 2 
56 G964/15 70 2 1 4 0 Growth Lt Vocal cord 1 3 1 1 
57 G1058/15 40 1 2 3 0 Growth Hypopharynx 2 3 2 2 
58 G1081/15 60 2 1 4 0 Growth Epiglottis 1 3 1 2 
59 G1107/15 70 2 1 4 0 Growth Supraglottis 2 3 1 2 
60 G1117/15 70 2 1 2 0 Growth Oropharynx 2 3 1 2 
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ABBREVIATIONS  FOR MASTER CHART 
Age group    
1. Age≤50 years   
2. Age>50 years  
Sex      
1. Male 
2. Female  
Site – HNSCC – Head and Neck Squamous Cell Carcinoma Site 
1. Oral cavity 
2. Oropharynx 
3. Hypopharynx 
4. Larynx 
Site – Oral SCC – Oral cavity Squamous cell Carcinoma 
0. Not part of the oral cavity 
1. Tongue 
2. Buccal mucosa 
3. Alveolus 
4. Soft palate 
5. Gingiva 
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HPE diag – Histopathological diagnosis 
1. HNSCC  Grade 1 
2. HNSCC  Grade 2 
3. HNSCC  Grade 3 
IHC diag - P
16INK4a
 expression 
0. Negative 
1. Sporadic 
2. Focal 
3. Diffuse 
Smoking – Smoking habit 
1. Yes 
2. No 
Alcohol –Alcohol consuming habit  
1. Yes 
2. No 
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ANNEXURE – III 
GLOSSARY 
CDKN2A      :   Cyclin dependent kinase inhibitor 2A 
DAB      :   Di amino benzidine 
EGFR    :   Epidermal growth factor receptor 
FFPE        :   Formalin fixed paraffin embedded 
HNSCC         :   Head and neck squamous cell carcinoma or     
     Oropharyngeal and upper respiratory tract squamous cell    
      carcinoma 
HPV            :   Human papilloma virus 
H&E           :   Haematoxylin & Eosin       
IHC         : Immunohistochemistry 
ISH         :   In Situ hybridisation 
MDSCC : Moderately differentiated squamous cell carcinoma 
OPSCC :  Oropharyngeal squamous cell carcinoma 
PCR  :  Polymerase chain reaction 
PBS  :  Phosphate buffer solution 
PDSCC :  Poorly differentiated squamous cell carcinoma 
RT-qPCR :  Real time quantitative polymerase chain reaction 
SCC  :  Squamous cell carcinoma 
TBS  :  Tris buffer solution 
WDSCC :  Well differentiated squamous cell carcinoma 
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